What happened, in summary

Karen Knetter learned she had non-small cell lung adenocarcinoma with an EGFR mutation during the COVID-19 lockdown period. While she was in the hospital, her oncologist’s encouragement helped her feel that she had a full team behind her. Karen described that support as a “wolf pack,” made up of her medical team, decades of lung cancer research, and the targeted therapy that was extending her life. Karen used her 2-year anniversary after diagnosis to advocate for better lung cancer funding, detection, and treatment. She wanted people to understand that lung cancer affects smokers, former smokers, and never-smokers, and that stigma should not determine research priorities or access to modern care. She also emphasized that targeted therapy exists because of research investment and that more funding could improve future outcomes. Karen passed away on September 7, 2024, 4 years after her lung cancer diagnosis. Her experience also highlights how biomarker testing can shape treatment options and give patients more time. Her story is best understood as both a patient experience and an advocacy message about EGFR testing, targeted therapy, and the need to fund lung cancer research. She wanted future patients to benefit from better detection, less stigma, and more research-backed options.